SAB Biotherapeutics (SABS) Total Liabilities (2020 - 2026)

SAB Biotherapeutics has reported Total Liabilities for 7 years, with the latest figure at $21.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 26.98% year-over-year to $21.2 million; the trailing twelve-month figure through Mar 2026 stood at $21.2 million (up 26.98% YoY), and the FY2025 full-year result was $21.3 million, up 16.95% from the prior year.
• Total Liabilities for Q1 2026 stood at $21.2 million, roughly flat from $21.3 million in the prior quarter.
• The five-year high for Total Liabilities was $27.2 million in Q1 2022, with the low at $13.1 million in Q3 2023.
• Historically, Total Liabilities has averaged $19.4 million across 5 years, with a median of $18.4 million in 2025.
• The largest YoY upside for Total Liabilities was 245.4% in 2022 against a maximum downside of 53.4% in 2022.
• SAB Biotherapeutics' Total Liabilities stood at $19.8 million in 2022, then jumped by 34.24% to $26.6 million in 2023, then slumped by 31.59% to $18.2 million in 2024, then gained by 16.95% to $21.3 million in 2025, then declined by 0.44% to $21.2 million in 2026.
• The last three Total Liabilities figures came in at $21.2 million (Q1 2026), $21.3 million (Q4 2025), and $18.4 million (Q3 2025), per Business Quant data.